Pharming & Santarus submit Ruconest BLA as HAE treatment is launched in Europe
This article was originally published in Scrip
Pharming and Santarus have submitted the BLA to the US FDA to obtain marketing approval for Rhucin (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.